Publication:
Management of treatment-naive Koos grade IV vestibular schwannomas using hypofractionated Gamma Knife radiosurgery: a retrospective single-institution study

dc.contributor.departmentKUH (Koç University Hospital)
dc.contributor.departmentSchool of Medicine
dc.contributor.kuauthorPeker, Selçuk
dc.contributor.kuauthorSamancı, Mustafa Yavuz
dc.contributor.kuauthorTepebaşılı, Mehmet Ali
dc.contributor.kuauthorDüzkalır, Ali Haluk
dc.contributor.kuauthorAskeroğlu, Mehmet Orbay
dc.contributor.schoolcollegeinstituteKUH (KOÇ UNIVERSITY HOSPITAL)
dc.contributor.schoolcollegeinstituteSCHOOL OF MEDICINE
dc.date.accessioned2025-03-06T20:59:47Z
dc.date.issued2024
dc.description.abstractWhile single-fraction Gamma Knife radiosurgery (GKRS) has shown efficacy in managing vestibular schwannomas (VSs), some concerns have been raised regarding its safety profile, particularly in the context of hearing preservation. Hypofractionation has emerged as a promising approach to improving the safety profile. This retrospective, single-institution study evaluated patient outcomes following hypofractionated GKRS (hf-GKRS) for treatment-na and iuml;ve Koos grade IV VSs. This study involved all patients with treatment-na and iuml;ve Koos grade IV VSs who underwent hf-GKRS (3 or 5 fractions) between January 2018 and June 2021, with a follow-up period of >= 36 months. The outcomes assessed included local control (LC), the preservation of serviceable hearing as determined by the Gardner-Robertson hearing scale, and procedure-related adverse events. Twenty-nine patients (14 females, median age 49 years) were treated with three different dose regimens: 21 patients received 18 Gy in 3 fractions, 6 patients received 20 Gy in 5 fractions, and 2 patients received 25 Gy in 5 fractions. Prior to treatment, 13 patients (44.8%) had serviceable hearing, one (3.4%) presented with facial palsy, and four (13.8%) had trigeminal nerve dysfunction. The median tumor volume was 10.8 cm3. During a median radiological follow-up period of 60 months (range, 36-78 months), LC was achieved in all patients. All 13 patients retained serviceable hearing at the last follow-up. Trigeminal nerve dysfunction occurred in one patient (3.4%), while another patient (3.4%) needed a ventriculoperitoneal shunt insertion due to new-onset hydrocephalus. No new-onset facial palsy was observed. hf-GKRS shows promise as an effective and safe primary or adjuvant treatment for Koos grade IV VSs with non-life-threatening or debilitating symptoms. Future studies with larger cohorts and extended follow-up periods are needed to validate these findings and to refine fractionation schemes.
dc.description.indexedbyWOS
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.publisherscopeInternational
dc.description.sponsoredbyTubitakEuN/A
dc.identifier.doi10.1007/s10143-024-03125-1
dc.identifier.eissn1437-2320
dc.identifier.issn0344-5607
dc.identifier.issue1
dc.identifier.quartileQ1
dc.identifier.scopus2-s2.0-85210448967
dc.identifier.urihttps://doi.org/10.1007/s10143-024-03125-1
dc.identifier.urihttps://hdl.handle.net/20.500.14288/27770
dc.identifier.volume47
dc.identifier.wos1363421600001
dc.keywordsHypofractionated radiosurgery
dc.keywordsGamma Knife radiosurgery
dc.keywordsKOOS grade
dc.keywordsRadiosurgery
dc.keywordsVestibular schwannoma
dc.language.isoeng
dc.publisherSpringer
dc.relation.ispartofNeurosurgical Review
dc.subjectClinical neurology
dc.subjectSurgery
dc.titleManagement of treatment-naive Koos grade IV vestibular schwannomas using hypofractionated Gamma Knife radiosurgery: a retrospective single-institution study
dc.typeJournal Article
dspace.entity.typePublication
local.contributor.kuauthorPeker, Selçuk
local.contributor.kuauthorSamancı, Mustafa Yavuz
local.contributor.kuauthorTepebaşılı, Mehmet Ali
local.contributor.kuauthorDüzkalır, Ali Haluk
local.contributor.kuauthorAskeroğlu, Mehmet Orbay
local.publication.orgunit1SCHOOL OF MEDICINE
local.publication.orgunit1KUH (KOÇ UNIVERSITY HOSPITAL)
local.publication.orgunit2KUH (Koç University Hospital)
local.publication.orgunit2School of Medicine
relation.isOrgUnitOfPublicationf91d21f0-6b13-46ce-939a-db68e4c8d2ab
relation.isOrgUnitOfPublicationd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isOrgUnitOfPublication.latestForDiscoveryf91d21f0-6b13-46ce-939a-db68e4c8d2ab
relation.isParentOrgUnitOfPublication055775c9-9efe-43ec-814f-f6d771fa6dee
relation.isParentOrgUnitOfPublication17f2dc8e-6e54-4fa8-b5e0-d6415123a93e
relation.isParentOrgUnitOfPublication.latestForDiscovery055775c9-9efe-43ec-814f-f6d771fa6dee

Files